Eli Lilly (#LLY) has received FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes. 🔹 Key Highlights - 💊 FDA approved Onswik for adults with type 2 diabetes. - 📅 The treatment is administered once weekly. - 💉 Lilly says it could reduce injections by more than 300 per year compared with once-daily basal insulin. - 🇺🇸 U.S. availability is expected in the coming months. - 🩺 The approval expands Lilly’s diabetes-care portfolio. - 📈 The product adds another treatment option for patients requiring basal insulin therapy. 💡 Why It Matters A once-weekly basal insulin could reduce the frequency of injections for eligible patients compared with daily basal insulin. The approval further expands Lilly’s presence in the diabetes-treatment market. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified